Antiangiogenic Therapy of Head and Neck Squamous Cell Carcinoma by Vascular Endothelial Growth Factor Antisense Therapy

Advances in Oto-Rhino-Laryngology

Volumn 62, Issue , 2005, Pages 103-120

  Riedel, Frank ^a   Götte, Karl ^a   Hörmann, Karl ^a   Grandis, Jennifer Rubin ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; MESSENGER RNA; VASCULOTROPIN A;

ANIMAL; APOPTOSIS; ARTICLE; CANCER TRANSPLANTATION; CELL PROLIFERATION; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEAD AND NECK TUMOR; METABOLISM; MOUSE; NEEDLE BIOPSY; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR CELL LINE; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BIOPSY, NEEDLE; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; REFERENCE VALUES; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 16644384212     PISSN: 00653071     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (34)

1. Lingen MW: Angiogenesis in the development of head and neck cancer and its inhibition by chemopreventive agents. Crit Rev Oral Biol Med 1999;10:153-164.
2. Mashberg A: Head and neck cancer. N Engl J Med 1993;328:1783-1784.
3. Dimery IW, Hong WK: Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 1993;85:95-111.
4. Hong WK, Bromer RH, Amato DA, Shapshay S, Vincent M, Vaughan C, Willett B, Katz A, Welch J, Fofonoff S, et al: Patterns of relapse in locally advanced head and neck cancer patients who achieved complete remission after combined modality therapy. Cancer 1985;56:1242-1245.
5. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31.
6. Kuehn R, Rojas W, Riedel F, Bergler W, Hörmann K: Tumour angiogenesis in head and neck squamous cell carcinoma. Br J Cancer 1998;77(suppl 1):27.
7. Risau W: Mechanisms of angiogenesis. Nature 1997;386:671-674.
8. Folkman J, Klagsbrun M: Angiogenetic factors. Science 1987;235:442-447.
9. Dvorak HF, Brown LF, Detmar M, Dvorak HM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am J Pathol 1995;146:1029-1039.
10. Ferrara N: The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995;36:127-137.
11. Zhang HT, Craft P, Scott PA, Ziehe M, Weich HA, Harris AL, Bicknell R: Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Nat Cancer Inst 1995;87:213-219.
12. Eisma RJ, Spiro JD, Kreutzer DL: Vascular endothelial growth factor expression in head and neck squamous cell carcinoma. Am J Surg 1997;174:513-517.
13. Mineta H, Miura K, Ogino T, Takebayashi S, Misawa K, Ueda Y, Suzuki I, Dictor M, Borg A, Wennerberg J: Prognostic value of vascular endothelial growth factor in head and neck squamous cell carcinomas. Br J Cancer 2000;83:775-781.
14. Salven P, Heikkilä P, Anttonen A, Kajanti M, Joensuu H: Vascular endothelial growth factor in squamous cell head and neck carcinoma: Expression and prognostic significance. Modern Pathol 1997;10:1128-1133.
15. Riedel F, Götte K, Schwalb J, Wirtz H, Bergler W, Hör mann K: Serum levels of vascular endothelial growth factor in patients with head and neck cancer. Eur Arch Otorhinolaryngol 2000;257:332-336.
16. Riedel F, Götte K, Schwalb J, Schäfer C, Hörmann K: Expression of vascular endothelial growth factor correlates with angiogenesis and p53 mutations in head and neck squamous cell carcinoma. Acta Otolaryngol 2000;120:105-111.
17. Riedel F, Götte K; Bergler W, Hörmann K: Inverse correlation of angiogenic and apoptotic markers in squamous cell carcinoma of the head and neck. Oncol Rep 2001;8:471-476.
18. Kim KJ, Li B, Winer J, Armanini M, Gillet N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-844.
19. Nakashima T, Hudson JM, Clayman GL: Antisense inhibition of vascular endothelial growth factor in human head and neck squamous cell carcinoma. Head Neck 2000;22:483-488.
20. Li M, Ye C, Feng C, Riedel F, Liu X, Zeng Q, Grandis JR: Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy. Clin Cancer Res 2002;8:3570-3578.
21. Petruzelli GJ, Snyderman CH, Johnson JT, Myers EN: Angiogenesis induced by head and neck squamous cell carcinoma xenografts in the chick embryo chorioallantioc membrane model. Ann Otol Rhinol Laryngol 1993;102:212-221.
22. Dray TG, Hardin NJ, Sofferman RA: Angiogenesis as a prognostic marker in early head and neck cancer. Ann Otol Rhinol Laryngol 1995;104:724-729.
23. Mirabelli CK, Bennett CF, Anderson K, Crooke ST: In vitro and in vivo pharmacologic activities of antisense oligonucleotides. Anticancer Drug Des 1991;6:647-661.
24. Smyth AP, Rook SL, Detmar M, Robinson GS: Antisense oligonucleotides inhibit vascular endothelial growth factor/vascular permeability factor expression in normal human epidermal keratinocytes. J Invest Dermatol 1997;108:523-526.
25. Zheng SX, Zhou LJ, Zhu XZ, Jin YX: Antisense oligodeoxynucleotide inhibits vascular endothelial growth factor in human glioma cells. Acta Pharmacol Sin 2000;21:211-214.
26. Field AK, Goodchild J: Antisense oligonucleotides: Rational drug design for genetic pharmacology. Exp Opin Invest Drugs 1995;4:799-821.
27. Nemunaitis J, Holmlund JT, Kraynak M, Richards D, Bruce J, Ognoskie N, Kwoh TJ, Geary R, Dorr A, Von Hoff D, Eckhardt SG: Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J Clin Oncol 1999;17:3586-3595.
28. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599.
29. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington JM: SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000;60:4152-4160.
30. Im SA, Gomez-Manzano C, Fueyo J, Liu TJ, Ke LD, Kim JS, Lee HY, Steck PA, Kyritsis AP, Yung WK: Anti-angiogenesis treatment for gliomas: Transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 1999;59:895-900.
31. Saleh M, Stacker SA, Wilks AF: Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 1996;56:393.
32. Ellis LM, Liu W, Wilson M: Down-regulation of vascular endothelial growth factor in human colon carcinoma cell lines by antisense transfection decreases endothelial cell proliferation. Surgery 1996;120:871-878.
33. Ke LD, Fueyo J, Chen X, Steck PA, Shi YX, Im SA, Yung WK: A novel approach to glioma gene therapy: Down-regulation of the vascular endothelial growth factor in glioma cells using ribozymes. Int J Oncol 1998;12:1391-1396.
34. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000;407:249-257.